Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...
Millions of people are taking compounded weight loss drugs. Now, they're about to disappear.
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
10 Best Growth Stocks to Buy for 2025
Economists around the world expect muted U.S. economic growth in the coming quarters, and some indicators have shown an increased likelihood of a 2025 recession in recent weeks. It may become ...
Becker's Hospital Review10h
10 drugs poised to be best-sellers in 2026
The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.
JD Supra13h
FDA Can Keep Tirzepatide off the Drug Shortage List, Judge Says
On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss ...
PSA: The 'Ozempic Dupes' Are Coming, and They Might Work Even Better
Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...